[中报]一致Ｂ(200028):2022年半年度报告摘要（英文版）
Short Form of the Stock: Sinopharm Accord /Accord B China National Accord Medicines Corporation Ltd. Summary of Semi-Annual Report 2022 I. Important Notice The summary of semi-annual report is excerpted from the full text of the semi-annual report. For the details, investors should carefully read the full text of the semi-annual report published on Juchao Information website (www.cninfo.com.cn) and Shenzhen Stock Exchange Website etc., appointed by CSRC. All directors are attended the Board Meeting for report deliberation. Prompt of modified auditing opinion □ Applicable √ Not applicable Profit distribution pre-plan of common stock or capitalizing of common reserves pre-plan deliberated by the Board in the reporting period □ Applicable √ Not applicable The Company plans not to carry out cash dividend and bonus distribution and capitalizing of common reserves Profit distribution pre-plan of preferred stock deliberated and approved by the Board in the reporting period □ Applicable √ Not applicable II. Basic information of the company 1. Company profile
□ Yes √ No
Unit: share
□ Applicable √ Not applicable Changes of controlling shareholders had no change in reporting period. Changes of actual controller in reporting period □ Applicable √ Not applicable Changes of actual controller had no change in reporting period. 5. Total preferred stock shareholders of the Company and shares held by top ten shareholders with preferred stock held The Company had no shareholders with preferred stock held in the reporting. 6. Bonds in existence as of the approval date of the semi-annual report □ Applicable √ Not applicable III. Important events On December 29, 2021, Sinopharm Holding Guoda Drugstore Co., Ltd. (hereinafter referred to as "Guoda Drugstore"), a controlling subsidiary of the Company, entered in to the Letter of Intent for Cooperation on the acquisition of some social retail pharmacy assets of the Company's controlling shareholders with Sinopharm Holding Hubei Co., Ltd. (hereinafter referred to as "Sinopharm Holding Hubei"). For details, please refer to the Sinopharm Accord: Announcement on Related Transactions of Controlling Shareholders' Fulfillment of Commitments and Solving the Problem of Horizontal Competition in Social Retail Pharmacy Assets" (Announcement No.:2021-42) disclosed on www.cninfo.com.cn dated December 31, 2021 . On June 27, 2022, the seventh meeting of the ninth board of directors of the company reviewed and approved the Proposal on Sinopharm Holding Guoda Drugstore Co., Ltd. Entrusting 100% Equity of Sinopharm Holding (Hubei) Hankou Pharmacy Co., Ltd. and Changing the Way to Solve the Horizontal Competition of Social Retail Pharmacy Assets. The board of directors agreed that Guoda Drugstore and Sinopharm Holding Hubei sign the Equity Escrow Agreement, changing the original method of solving the horizontal competition of social retail pharmacy assets from acquisition to escrow, that is, from Guoda Drugstore purchasing 51% equity of Sinopharm Holding (Hubei) Hankou Pharmacy Co., Ltd. to escrowing 100% of its equity. On June 27, 2022, the two parties formally signed the Equity Escrow Agreement. For details, please refer to the Sinopharm Accord: Progress Announcement on the Controlling Shareholder's Fulfillment of Commitments and Solving the Problem of Horizontal Competition in Social Retail Pharmacy Assets" (Announcement No.:2022-28) disclosed on www.cninfo.com.cn dated June 29, 2022. China National Accord Medicines Corporation Ltd. Legal representative: Lin Zhaoxiong August 31, 2022 中财网
 |